Trial Profile

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Hormone Receptor-Positive HER2-Negative Breast Cancer (MORPHEUS-HR+ Breast Cancer)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 23 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abemaciclib (Primary) ; Atezolizumab (Primary) ; Bevacizumab (Primary) ; Entinostat (Primary) ; Exemestane (Primary) ; Fulvestrant (Primary) ; Ipatasertib (Primary) ; Tamoxifen (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms MORPHEUS; MORPHEUS-HR+ Breast Cancer
Sponsors Roche

21 Oct 2024 Status changed from active, no longer recruiting to completed.
05 Sep 2024 Planned End Date changed from 31 Dec 2024 to 12 Sep 2024.
04 Sep 2024 Planned primary completion date changed from 31 Dec 2024 to 12 Sep 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com